tiprankstipranks

Structure Therapeutics price target raised to $79 from $50 at Jefferies

Jefferies raised the firm’s price target on Structure Therapeutics to $79 from $50 and keeps a Buy rating on the shares after the company announced results from the Phase 1b multiple ascending dose, MAD, study of its highly selective oral GLP-1 receptor agonist, GSBR-1290, in healthy overweight or obese individuals. Today’s data were “de-risking with impressive weight loss and generally tolerated profile,” says the analyst, who has confidence about GSBR-1290’s profile based on the data to-date and the development plan.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on GPCR:

Disclaimer & DisclosureReport an Issue